Literature DB >> 22045276

Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report.

Samia Arifi1,2, El Mehdi Tazi3, Omar El Mesbahi4, Hassan Errihani3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22045276     DOI: 10.1007/s12029-011-9340-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  14 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

4.  Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

Authors:  Jose Lutzky; Juergen Bauer; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-29       Impact factor: 4.693

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

7.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 8.  Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Authors:  Nagendra Natarajan; Sucheta Telang; Donald Miller; Jason Chesney
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

9.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

Authors:  Ann W Gramza; Christopher L Corless; Michael C Heinrich
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

10.  Lack of clinical efficacy of imatinib in metastatic melanoma.

Authors:  S Ugurel; R Hildenbrand; A Zimpfer; P La Rosée; P Paschka; A Sucker; P Keikavoussi; J C Becker; W Rittgen; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.